Long-term safety and effectiveness of growth hormone therapy in Korean children with growth disorders: 5-year results of LG Growth Study.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as an observational study.

Who Took Part

The study group was 2,024 patients.

PubMed indexes the participants as young children, children, teenagers and young adults, both men and women.

The study patients were followed-up till two years after the epiphyseal closure, with visits scheduled every six months.

The results of the interim analysis of a 5-year accumulated data for 2,024 patients (7,342 patient-years, PY) are presented.

How the Study Was Run

The outcome measures included the incidence of adverse events (AEs, in particular, neoplasia, glucose intolerance and hypothyroidism), as well as height standard deviation score (Ht SDS) and annual height velocity.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Body Height, Glycated Hemoglobin, Growth Disorders, Human Growth Hormone, Infant, Small for Gestational Age and Insulin-Like Growth Factor Binding Protein 3.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 2,024 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (PloS one), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.